Sectors & IndustriesHealthcare

Best Healthcare Stocks to Buy Now (2025)

Top healthcare stocks in 2025 ranked by overall Due Diligence Score. See the best healthcare stocks to buy now, according to analyst forecasts for the healthcare sector.

According to Zen Ratings, our proprietary rating system that evaluates 115 factors proven to drive growth in stocks and assigns each stock in our system an overall letter grade as well as 7 individual Component Grades for Value, Growth, Momentum, Sentiment, Safety, Financials, and proprietary AI algorithms, the 3 best healthcare stocks to buy right now are:

Pediatrix Medical Group (NYSE:MD) is the #1 top healthcare stock out of 1095 with a Zen Rating of A. Stocks with a rating of A have had an average return of +32.52% per year. Learn more.

The Component Grade breakdown for Pediatrix Medical Group (NYSE:MD) is: Value: A, Growth: B, Momentum: B, Sentiment: A, Safety: B, Financials: B, and AI: C.

Pediatrix Medical Group (NYSE:MD) has a Due Diligence Score of 41, which is 15 points higher than the healthcare sector average of 26. It passed 13 out of 33 due diligence checks and has strong fundamentals. Pediatrix Medical Group has seen its stock return 67.01% over the past year, overperforming other healthcare stocks by 97 percentage points.

Pediatrix Medical Group has an average 1 year price target of $21.33, a downside of -13.46% from Pediatrix Medical Group's current stock price of $24.65.

Pediatrix Medical Group stock has a consensus Hold recommendation according to Wall Street analysts. Of the 3 analysts covering Pediatrix Medical Group, 0% have issued a Strong Buy rating, 0% have issued a Buy, 100% have issued a Hold, while 0% have issued a Sell rating, and 0% have issued a Strong Sell.

Collegium Pharmaceutical (NASDAQ:COLL) is the #2 top healthcare stock out of 1095 with a Zen Rating of A. Stocks with a rating of A have had an average return of +32.52% per year. Learn more.

The Component Grade breakdown for Collegium Pharmaceutical (NASDAQ:COLL) is: Value: A, Growth: B, Momentum: B, Sentiment: B, Safety: C, Financials: B, and AI: B.

Collegium Pharmaceutical (NASDAQ:COLL) has a Due Diligence Score of 50, which is 24 points higher than the healthcare sector average of 26. It passed 17 out of 33 due diligence checks and has strong fundamentals. Collegium Pharmaceutical has seen its stock return 48.1% over the past year, overperforming other healthcare stocks by 78 percentage points.

Collegium Pharmaceutical has an average 1 year price target of $46.67, an upside of 2.34% from Collegium Pharmaceutical's current stock price of $45.60.

Collegium Pharmaceutical stock has a consensus Strong Buy recommendation according to Wall Street analysts. Of the 3 analysts covering Collegium Pharmaceutical, 33.33% have issued a Strong Buy rating, 66.67% have issued a Buy, 0% have issued a Hold, while 0% have issued a Sell rating, and 0% have issued a Strong Sell.

Enhabit (NYSE:EHAB) is the #3 top healthcare stock out of 1095 with a Zen Rating of A. Stocks with a rating of A have had an average return of +32.52% per year. Learn more.

The Component Grade breakdown for Enhabit (NYSE:EHAB) is: Value: C, Growth: A, Momentum: C, Sentiment: A, Safety: B, Financials: B, and AI: B.

Enhabit (NYSE:EHAB) has a Due Diligence Score of 16, which is -10 points lower than the healthcare sector average of 26. Although this number is below the industry average, our proven quant model rates EHAB as a "A".It passed 5 out of 33 due diligence checks and has weak fundamentals. Enhabit has seen its stock return 15.62% over the past year, overperforming other healthcare stocks by 46 percentage points.

Enhabit has an average 1 year price target of $8.50, a downside of -3.52% from Enhabit's current stock price of $8.81.

Enhabit stock has a consensus Hold recommendation according to Wall Street analysts. Of the 1 analyst covering Enhabit, 0% have issued a Strong Buy rating, 0% have issued a Buy, 100% have issued a Hold, while 0% have issued a Sell rating, and 0% have issued a Strong Sell.

Out of 71 healthcare stocks that have issued dividends in the past year, the 3 healthcare stocks with the highest dividend yields are:

Dominari Holdings (NASDAQ:DOMH) has an annual dividend yield of 12.22%, which is 10 percentage points higher than the healthcare sector average of 1.91%.

Dominari Holdings's dividend payout ratio of 8.4% indicates that its high dividend yield is sustainable for the long-term.

Spok Holdings (NASDAQ:SPOK) has an annual dividend yield of 9.54%, which is 8 percentage points higher than the healthcare sector average of 1.91%. Spok Holdings's dividend payout is not stable, having dropped more than 10% two times in the last 10 years. Spok Holdings's dividend has shown consistent growth over the last 10 years.

Spok Holdings's dividend payout ratio of 154.3% indicates that its high dividend yield might not be sustainable for the long-term.

Perrigo Co (NYSE:PRGO) has an annual dividend yield of 6.63%, which is 5 percentage points higher than the healthcare sector average of 1.91%. Perrigo Co's dividend payout is stable, having never dropped by more than 10% in the last 10 years. Perrigo Co's dividend has shown consistent growth over the last 10 years.

Perrigo Co's dividend payout ratio of -301.6% indicates that its high dividend yield might not be sustainable for the long-term.

Healthcare stocks were up 1.68% in the last day, and up 5.15% over the last week. Pharmacyte Biotech was the among the top gainers in the healthcare sector, gaining 36.92% yesterday.

PharmaCyte Biotech shares are trading higher after the company announced monetization of its stake in Femasys.

Based on the Valuation rating, one of the 7 components of a stocks overall Zen Ratings grade, which evaluates factors including estimated earnings yield, earnings before interest and taxes/enterprise value, cash flow yield, free cash flow to price, and price-to-earnings growth (PEG ratio), the 3 most undervalued healthcare stocks right now are:

Harmony Biosciences Holdings (NASDAQ:HRMY) is the most undervalued healthcare stock based on its Valuation Rating of A. Valuation is one of 7 Component Grades used to calculate the overall Zen Rating.

Harmony Biosciences Holdings has a valuation score of 71, which is 54 points higher than the healthcare sector average of 17. It passed 5 out of 7 valuation due diligence checks.

Harmony Biosciences Holdings's stock has gained 1.82% in the past year. It has overperformed other stocks in the healthcare sector by 32 percentage points.

Organon & Co (NYSE:OGN) is the second most undervalued healthcare stock based on its Valuation Rating of A. Valuation is one of 7 Component Grades used to calculate the overall Zen Rating.

Organon & Co has a valuation score of 71, which is 54 points higher than the healthcare sector average of 17. It passed 5 out of 7 valuation due diligence checks.

Organon & Co's stock has dropped -53.56% in the past year. It has underperformed other stocks in the healthcare sector by -24 percentage points.

Bausch Health Companies (NYSE:BHC) is the third most undervalued healthcare stock based on its Valuation Rating of A. Valuation is one of 7 Component Grades used to calculate the overall Zen Rating.

Bausch Health Companies has a valuation score of 57, which is 40 points higher than the healthcare sector average of 17. It passed 4 out of 7 valuation due diligence checks.

Bausch Health Companies's stock has dropped -20.5% in the past year. It has overperformed other stocks in the healthcare sector by 10 percentage points.

54.63% of healthcare stocks rated by analysts are a strong buy right now. On average, analysts expect healthcare stocks to rise by 21.65% over the next year.

7.83% of healthcare stocks have a Zen Rating of A (Strong Buy), 13.2% of healthcare stocks are rated B (Buy), 46.14% are rated C (Hold), 24.07% are rated D (Sell), and 8.76% are rated F (Strong Sell).